Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit
Executive Summary
The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.
You may also be interested in...
NIH Would ‘Revolutionize’ Cancer Trial Recruitment With New ‘Moonshot’ Money
Rick Pazdur's wish for the National Cancer Institute to help industry speed US trial enrollment and diversity could get a boost if Congress fulfills Biden’s new fiscal year Cancer Moonshot funding request.
Biden’s Second ‘Moonshot’: A National Subscription Model To Eliminate Hep C
A federal plan that would provide a lump sum to drug makers to increase hepatitis C treatment, building on subscription models used in Louisiana and Washington state, was previewed by Francis Collins, former NIH director and current special advisor to President Biden.
ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment
Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.